Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2024 Mar 05; 185:186-193.